For the year ending 2025-12-31, CRBP had $11,294K increase in cash & cash equivalents over the period. -$64,498K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -78,537 |
| Stock-based compensation expense | 6,288 |
| Depreciation expense | 233 |
| Net amortization of premiums and discounts on investments | 1,366 |
| Amortization of debt discount | 0 |
| Other | 229 |
| Decrease (increase) in prepaid expenses and other current assets | -634 |
| Decrease in other assets | 0 |
| Decrease in operating lease right-of-use asset | -1,051 |
| Decrease in other long-term liabilities | 0 |
| (decrease) increase in accounts payable | -2,349 |
| Increase (decrease) in accrued expenses | 11,390 |
| Decrease in operating lease liabilities | -1,606 |
| Net cash used in operating activities | -64,491 |
| Purchases of property and equipment | 7 |
| Purchases of investments | 163,091 |
| Proceeds from sales and maturities of investments | 161,457 |
| Net cash used in investing activities | -1,641 |
| Proceeds from issuance of common stock and pre-funded warrants, net | 77,426 |
| Repayment of short-term borrowings | 0 |
| Repayment of long-term borrowings | 0 |
| Net cash provided by (used in) financing activities | 77,426 |
| Net increase in cash, cash equivalents, and restricted cash | 11,294 |
| Cash, cash equivalents, and restricted cash at beginning of the period | 17,868 |
| Cash, cash equivalents, and restricted cash at end of the period | 29,162 |
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. (CRBP)